Eli Lilly made a push in blood cancer at this year’s European Hematology Association presenting data for Jaypirca as well as its first-ever clinical trial results in myelofibrosis.
Eli Lilly made a push in blood cancer at this year’s European Hematology Association meeting in Stockholm over the weekend.
The drugmaker presented data for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
In patients with BTK-pretreated chronic lymphocytic leukemia (CLL), AbbVie and Roche’s Venclexta (venetoclax) is the drug to…
Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion…
ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries
In a plenary session at the 2026 European Hematology Association (EHA) annual meeting in Stockholm, Johnson & Johnson brought to…
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck…
